GlassScriptPhysician profile
Peter N Le
NPI 1942460209
$138,055.08
in general payments reported to CMS, 2019-2025
35 companies · $68K in 2025
The $68K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,472 · 2020: $2,053 · 2021: $7,370 · 2022: $4,716 · 2023: $12K · 2024: $39K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Travel and Lodging: $11K · Food and Beverage: $10K · Education: $48.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $97,203.75 |
| Travel and Lodging | $10,749.15 |
| Food and Beverage | $10,442.68 |
| Education | $48.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $54,181.86 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $34,830.75 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $25,729.09 | 2019-2025 | |
| Ardelyx, INC. | $8,975.00 | 2022-2025 | Ibsrela |
| Allergan, INC. | $6,583.96 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $2,453.30 | 2019-2024 | Linzess |
| Janssen Biotech, INC. | $741.40 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $731.81 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $729.34 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $589.38 | 2019-2025 | |
| Lilly USA, LLC | $400.77 | 2023-2025 | Omvoh |
| Genzyme Corporation | $346.77 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $290.89 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $287.71 | 2022-2025 | |
| Qol Medical, LLC | $216.37 | 2022-2025 | Sucraid, Sucraid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $116.94 | 2019-2025 | Ocaliva |
| Organon LLC | $100.37 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $94.37 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $78.15 | 2019-2024 | Rebyota |
| Merck Sharp & Dohme LLC | $71.79 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $65.51 | 2021-2022 | |
| Redhill Biopharma INC. | $58.99 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Ucb, INC. | $52.87 | 2019 | |
| Madrigal Pharmaceuticals | $51.55 | 2024-2025 | Resmetirom, Rezdiffra |
| Micro-Tech Endoscopy USA, INC. | $50.54 | 2021 | |
| Laborie Medical Technologies Corp. | $42.46 | 2023 | |
| Shire North American Group INC | $39.20 | 2019 | |
| Daiichi Sankyo INC. | $30.33 | 2024 | Injectafer |
| Amgen INC. | $21.59 | 2025 | Uplizna |
| Braintree Laboratories, INC. | $19.94 | 2021 | |
| Alfasigma USA, INC. | $17.51 | 2020 | |
| Albireo Pharma, INC. | $15.36 | 2023 | Bylvay |
| Ethicon US, LLC | $15.08 | 2020 | |
| Novo Nordisk INC | $13.65 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.